Author:
Fan Yibo,Che Xiaofang,Hou Kezuo,Zhang Min,Wen Ti,Qu Xiujuan,Liu Yunpeng
Funder
National Science and Technology Major Project of the Ministry of Science and Technology of China
The National Key Research and Development Program of China
National Natural Science Foundation of China
Science and Technology Plan Project of Liaoning Province
The General Project of Liaoning Province Department of Education
Reference25 articles.
1. The future of immune checkpoint therapy;Sharma;Science,2015
2. Y.J. Bang, Relationship between PD-L1 expression and clinical outcomes in patients with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in KEYNOTE-012. ASCO; Chicago. United State of America. 2015.5.29-6.2, 2015.
3. Pembrolizumab and nivolumab: pd-1 inhibitors for advanced melanoma;Ivashko;Am. J. Health Syst. Pharm.,2016
4. Nivolumab and pembrolizumab for non-small cell lung cancer;Morgensztern;Clin. Cancer Res.,2016
5. Migration is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression;Chen;Nat. Commun.,2014
Cited by
29 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献